IP Verse

Cl Biosciences competitive analysis

Loading summary...

Latest patents of Cl Biosciences opposed by its competitors

Explore Cl Biosciences's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Last updated on: Oct 23, 2025
Patent NumberGrant DateTitleTotal Oppositions
EP3071206
Feb 17, 2021Gastrin Antagonists (Eg Yf476, Netazepide) For Treatment And Prevention Of Osteoporosis1

Latest publications and patents of Cl Biosciences New

Explore the latest publications and patents granted to Cl Biosciences, showcasing their recent innovations and technological advancements.

Last updated on: Oct 18, 2025
Publication NumberPublication DateTitleLegal Status

Get instant update for new patents of Cl Biosciences

EP3071206
Feb 17, 2021Gastrin Antagonists (Eg Yf476, Netazepide) For Treatment And Prevention Of OsteoporosisGranted And Under Opposition

Latest PTAB cases involving Cl Biosciences

Discover the latest PTAB cases involving Cl Biosciences, highlighting their recent legal challenges and patent disputes.

Peer Comparison New

IP litigation analysis comparing Cl Biosciences with top 3 competitors. Includes complete PTAB case data and opposition data from 2018 onwards.

Last updated on: Oct 23, 2025
CompanyOppositions FiledOppositions FacedPTAB Cases FiledPTAB Cases Faced
CL BIOSCIENCES - 1 - -
TRIO MEDICINES1 - - -